Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 50 3
Cytomegalovirus Infections 40 69

External Ids:

UMLS 69 C0010823

Summaries for Cytomegalovirus Infection

NINDS : 50 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and erythema multiforme, and has symptoms including pruritus and fever. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, kidney and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

MedlinePlus : 40 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Once CMV is in a person’s body, it stays there for life and can reactivate. Most people infected with CMV show no signs or symptoms. However, CMV infection can cause serious health problems for people with weakened immune systems, as well as babies infected with the virus before they are born (congenital CMV).

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 541)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 34.2 IFNG IL10 RAG1
2 erythema multiforme 30.2 ICAM1 IFNG TNF
3 pouchitis 30.0 CXCL8 IL10
4 vasculitis 30.0 ICAM1 SELE TNF VCAM1
5 microscopic polyangiitis 29.7 IL10 KIR3DL1 TNF
6 pneumonia 29.7 CXCL8 IL10 IL6 TNF
7 myasthenia gravis 29.6 IFNG IL10 TNF
8 ileocolitis 29.6 IL2RA TNF
9 colitis 29.6 CXCL8 IFNG IL10 IL6 TNF
10 choroiditis 29.6 IL10 TNF
11 hematopoietic stem cell transplantation 29.5 IFNG IL10 IL6 KIR3DL1 TNF
12 ulcerative colitis 29.5 CXCL8 IFNG IL10 IL6 TNF
13 toxoplasmosis 29.5 IFNG IL10 IL6 TNF
14 crohn's disease 29.5 IFNG IL10 IL6 TNF
15 perinatal necrotizing enterocolitis 29.5 CXCL8 IL6 TNF
16 pertussis 29.5 IL10 IL6 TNF
17 listeriosis 29.5 IL10 IL6 TNF
18 chronic graft versus host disease 29.4 IFNG IL10 IL2RA
19 gingivitis 29.4 CXCL8 IL6 TNF
20 central nervous system vasculitis 29.4 IFNG IL6 TNF
21 peripheral vascular disease 29.4 IL6 SELE VCAM1
22 myocarditis 29.3 ICAM1 IL6 TNF
23 mycobacterium tuberculosis 1 29.3 IFNG IL10 TNF
24 arteriovenous fistula 29.3 IL6 SELE
25 acute respiratory distress syndrome 29.3 CXCL8 IL6 TNF
26 acute transverse myelitis 29.2 CXCL8 IL10 IL6
27 anterior uveitis 29.2 IL2RA IL6 TNF
28 acute graft versus host disease 29.2 IFNG IL10 IL2RA TNF
29 arteriosclerosis 29.2 ICAM1 IL10 IL6 SELE VCAM1
30 arteries, anomalies of 29.1 ICAM1 IL6 SELE TNF VCAM1
31 monocytic leukemia 29.1 CXCL8 IFNG IL6 TNF
32 acquired immunodeficiency syndrome 29.1 IFNG IL10 IL2RA IL6 TNF
33 periodontal disease 29.1 CXCL8 IL6 TNF
34 graft-versus-host disease 29.1 FAS IFNG IL10 IL6 TNF
35 acute pancreatitis 29.0 CXCL8 IL10 IL6
36 transverse myelitis 29.0 CXCL8 IL10 IL6 TNF
37 otitis media 29.0 CXCL8 IL10 IL6 TNF
38 lymphopenia 28.9 FAS IFNG IL2RA RAG1
39 autoimmune lymphoproliferative syndrome 28.9 FAS IL10 IL2RA MTOR
40 arthritis 28.9 CXCL8 IFNG IL10 IL6 TNF
41 uveitis 28.9 ICAM1 IFNG IL10 IL2RA TNF
42 chlamydia 28.8 CXCL8 IFNG IL10 IL6 TNF
43 bronchiolitis obliterans 28.6 CXCL8 IFNG IL10 IL6 TNF
44 gastroenteritis 28.6 CXCL8 IFNG IL10 IL6 TNF
45 bronchiolitis 28.6 CXCL8 IFNG IL10 IL6 TNF
46 meningitis 28.6 CXCL8 IFNG IL10 IL6 TNF
47 periodontitis 28.6 CXCL8 IFNG IL10 IL6 TNF
48 hemophagocytic lymphohistiocytosis 28.6 CXCL8 FAS IFNG IL10 IL2RA TNF
49 wegener granulomatosis 28.6 CXCL8 IFNG IL10 IL6 SELE TNF
50 human immunodeficiency virus type 1 28.5 HLA-G IFNG IL10 IL6 KIR3DL1 TNF

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


pruritus, fever

GenomeRNAi Phenotypes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CXCL8 FAS ICAM1 IL10 IL2RA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CXCL8 FAS ICAM1 IL10 IL2RA TNF

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.3 FAS GJB2 ICAM1 IFNG IL10 IL6
2 cellular MP:0005384 10.29 RAG1 SELE TNF VCAM1 FAS GJB2
3 growth/size/body region MP:0005378 10.29 RAG1 SELE TNF VCAM1 FAS GJB2
4 homeostasis/metabolism MP:0005376 10.29 GJB2 HLA-G ICAM1 IFNG IL10 IL2RA
5 hematopoietic system MP:0005397 10.27 FAS HLA-G ICAM1 IFNG IL10 IL2RA
6 immune system MP:0005387 10.27 VCAM1 FAS GJB2 HLA-G ICAM1 IFNG
7 endocrine/exocrine gland MP:0005379 10.18 FAS ICAM1 IFNG IL10 IL2RA IL6
8 mortality/aging MP:0010768 10.15 SELE TNF VCAM1 FAS GJB2 ICAM1
9 digestive/alimentary MP:0005381 10.14 FAS ICAM1 IFNG IL10 IL2RA IL6
10 integument MP:0010771 10.09 FAS GJB2 ICAM1 IFNG IL10 IL6
11 liver/biliary system MP:0005370 9.95 FAS IFNG IL10 IL6 RAG1 SELE
12 neoplasm MP:0002006 9.87 FAS ICAM1 IFNG IL10 IL6 RAG1
13 respiratory system MP:0005388 9.81 RAG1 SELE TNF FAS IFNG IL10
14 no phenotypic analysis MP:0003012 9.8 GJB2 IFNG IL10 KLRB1 MTOR TNF
15 skeleton MP:0005390 9.56 FAS GJB2 IFNG IL10 IL6 MTOR
16 vision/eye MP:0005391 9.32 FAS GJB2 ICAM1 IFNG IL10 IL2RA

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
2
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
4
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
5
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
8
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
9
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 4428-95-9, 63585-09-1 3415
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
12
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
13
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
14
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
15
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1 57-66-9 4911
16
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
18
Infliximab Approved Phase 4 170277-31-3
19
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Pancrelipase Approved, Investigational Phase 4 53608-75-6
22
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
23
Azathioprine Approved Phase 4 446-86-6 2265
24 tannic acid Approved, Nutraceutical Phase 4
25
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 4408-78-0 546
26 triamcinolone acetonide Phase 4
27 Prednisolone acetate Phase 4,Phase 3
28 glucocorticoids Phase 4,Phase 3
29 Methylprednisolone acetate Phase 4,Phase 3
30 Methylprednisolone Hemisuccinate Phase 4,Phase 3
31 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1
33 Gastrointestinal Agents Phase 4,Phase 1
34 Neuroprotective Agents Phase 4
35 Triamcinolone diacetate Phase 4
36 Triamcinolone hexacetonide Phase 4
37 Cyclosporins Phase 4,Phase 3
38 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Hormone Antagonists Phase 4,Phase 3,Phase 2
41 Hormones Phase 4,Phase 3,Phase 2
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
46 Antiemetics Phase 4
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 2
49 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
50 Antilymphocyte Serum Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 341)

# Name Status NCT ID Phase Drugs
1 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
3 Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients Unknown status NCT00364052 Phase 4 oral Valganciclovir vs oral Ganciclovir
4 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
5 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients Completed NCT00436384 Phase 4
8 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
9 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
10 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
11 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
12 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
13 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
14 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
15 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
16 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
17 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
18 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
19 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
20 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
21 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
22 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
23 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
24 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
25 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
26 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
27 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
28 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
29 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
30 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
31 PTH - Preemptive Treatment for Herpesviridae Recruiting NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
32 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
33 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Active, not recruiting NCT02328963 Phase 4 Everolimus;mycophenolic acid
34 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Active, not recruiting NCT02550639 Phase 4
35 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients Active, not recruiting NCT01552369 Phase 4 Prophylaxis with Valganciclovir
36 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
37 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
38 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
39 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
40 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
41 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
42 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
43 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
44 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
45 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
46 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
47 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir
48 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
49 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation Completed NCT00372229 Phase 3 Pre-emptive therapy;valganciclovir [Valcyte]
50 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir;Valganciclovir

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

38
T Cells, Kidney, Eye, Liver, Testes, Lung, Brain

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 1420)
# Title Authors Year
1
Human cytomegalovirus infection and coronary heart disease: a systematic review. ( 29409508 )
2018
2
Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. ( 29359492 )
2018
3
MicroRNA transcriptome analysis of porcine vital organ responses to immunosuppressive porcine cytomegalovirus infection. ( 29347945 )
2018
4
Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection. ( 29348920 )
2018
5
No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single centre. ( 29404743 )
2018
6
Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. ( 29424814 )
2018
7
Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection. ( 29441223 )
2018
8
Congenital Cytomegalovirus Infection: Update on Treatment: Scientific Impact Paper No. 56. ( 29139205 )
2018
9
Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults. ( 29434600 )
2018
10
Healthcare costs attributable to congenital cytomegalovirus infection. ( 29363491 )
2018
11
Congenital Cytomegalovirus Infection and the Occurrence of Cystic Periventricular Leukomalacia. ( 29217314 )
2018
12
Relevant pericardial effusion caused by cytomegalovirus infection in an immunocompetent patient: a case report. ( 29347961 )
2018
13
A rare presentation of cytomegalovirus infection in an immunocompetent patient. ( 29410021 )
2018
14
Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections. ( 29343580 )
2018
15
Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir. ( 29407294 )
2018
16
Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. ( 29392650 )
2018
17
Results of a Targeted Screening Program for Congenital Cytomegalovirus Infection in Infants Who Fail Newborn Hearing Screening. ( 29373759 )
2018
18
Congenital cytomegalovirus infection in Central Germany: an underestimated risk. ( 28624987 )
2017
19
Venous thromboembolism related to cytomegalovirus infection: A case report and literature review. ( 29390512 )
2017
20
Neonatal and long-term ophthalmological findings in infants with symptomatic and asymptomatic congenital cytomegalovirus infection. ( 29149633 )
2017
21
T and B Cell Markers in Dried Blood Spots of Neonates with Congenital Cytomegalovirus Infection: B Cell Numbers at Birth Are Associated with Long-Term Outcomes. ( 27903736 )
2017
22
Cytomegalovirus infection in a splenectomized with I^-thalassemia major: immunocompetent or immunosuppressed? ( 28680595 )
2017
23
High prevalence of cytomegalovirus infection in surgical intestinal specimens from infants with necrotizing enterocolitis and spontaneous intestinal perforation: A retrospective observational study. ( 28633098 )
2017
24
RMND1-Related Leukoencephalopathy With Temporal Lobe Cysts and Hearing Loss-Another Mendelian Mimicker of Congenital Cytomegalovirus Infection. ( 27843092 )
2017
25
Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women. ( 27986675 )
2017
26
Pulmonary Calcification in a Congenital Cytomegalovirus Infection. ( 28807358 )
2017
27
Congenital Cytomegalovirus Infection in Children with Autism Spectrum Disorder: Systematic Review and Meta-Analysis. ( 29185167 )
2017
28
Juvenile myelomonocytic leukemia in an infant with congenital human immunodeficiency virus and cytomegalovirus infection. ( 28612348 )
2017
29
Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: A systematic review. ( 28876493 )
2017
30
Congenital Cytomegalovirus Infection: Prognostic Value of Maternal DNAemia at Amniocentesis. ( 27986666 )
2017
31
Cellular responses to human cytomegalovirus infection: Induction of a mesenchymal-to-epithelial transition (MET) phenotype. ( 28874566 )
2017
32
A case of cytomegalovirus infection with splenic infarction and an esophageal ulcer in an immunocompetent adult. ( 28679983 )
2017
33
Preventing Congenital Cytomegalovirus Infection. ( 28825308 )
2017
34
Erdheim-Chester disease with unusual clinicopathological features complicated by DRESS syndrome, disseminated Cytomegalovirus infection and hemophagocytic lymphohistiocytosis. ( 28418177 )
2017
35
Congenital Cytomegalovirus Infection after a Multiple-Birth Pregnancy. ( 28763424 )
2017
36
High Seroprevalence of CMV Among Women of Childbearing Age Implicates High Burden of Congenital Cytomegalovirus Infection in Poland. ( 28735326 )
2017
37
Cytomegalovirus infection: the neurodevelopmental peptide signatures. ( 28875854 )
2017
38
Congenital Cytomegalovirus Infection: Maternal-Child HLA-C, HLA-E, and HLA-G Affect Clinical Outcome. ( 29354123 )
2017
39
Intrauterine fetal death due to congenital cytomegalovirus infection. ( 28606416 )
2017
40
Early Stochastic Dynamics in Human Cytomegalovirus Infection. ( 28839088 )
2017
41
Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. ( 28679960 )
2017
42
Knowledge of Human Cytomegalovirus Infection and Prevention in Pregnant Women: A Baseline, Operational Survey. ( 28831237 )
2017
43
Neonatal screening parameters in infants with congenital Cytomegalovirus infection. ( 28847685 )
2017
44
Pathogenesis of developmental anomalies of the central nervous system induced by congenital cytomegalovirus infection. ( 28074532 )
2017
45
Acute macular neuroretinopathy associated with subclinical cytomegalovirus infection. ( 27444308 )
2017
46
Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience. ( 28923622 )
2017
47
Severe neonatal cytomegalovirus infection: about a case. ( 28904689 )
2017
48
Primary Cytomegalovirus Infection Causing Guillain-BarrAc Syndrome in a Living Renal Allograft Recipient. ( 29348962 )
2017
49
Symptomatic Congenital Cytomegalovirus Infection in Children of Seropositive Women. ( 28649563 )
2017
50
Long-term Outcomes of Cochlear Implantation in Children With Congenital Cytomegalovirus Infection. ( 28604578 )
2017

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CXCL8 HLA-G ICAM1 IFNG IL10 IL2RA
2
Show member pathways
13.68 CXCL8 FAS IFNG IL10 IL2RA IL6
3
Show member pathways
13.57 CXCL8 ICAM1 IFNG IL10 IL2RA IL6
4
Show member pathways
13.43 CXCL8 FAS IL10 IL2RA IL6 MTOR
5
Show member pathways
13.37 CXCL8 HLA-G ICAM1 IFNG IL10 IL2RA
6
Show member pathways
13.01 FAS HLA-G IL2RA IL6 MTOR TNF
7 12.9 CXCL8 FAS IFNG IL2RA IL6 MTOR
8
Show member pathways
12.82 CXCL8 FAS HLA-G ICAM1 IFNG IL2RA
9
Show member pathways
12.7 CXCL8 FAS HLA-G ICAM1 IFNG IL10
10
Show member pathways
12.68 IFNG IL10 IL2RA IL6 MTOR TNF
11
Show member pathways
12.61 CXCL8 FAS IFNG IL10 IL6 TNF
12
Show member pathways
12.61 CXCL8 FAS HLA-G ICAM1 IL6 MTOR
13
Show member pathways
12.59 FAS HLA-G ICAM1 IFNG KIR3DL1 TNF
14 12.59 FAS IFNG IL10 IL2RA RAG1 TNF
15
Show member pathways
12.54 HLA-G ICAM1 IFNG VCAM1
16
Show member pathways
12.5 FAS IFNG IL10 IL6 TNF
17 12.49 HLA-G ICAM1 IL2RA IL6 TNF VCAM1
18
Show member pathways
12.44 IFNG IL10 IL2RA IL6 MTOR
19
Show member pathways
12.43 ICAM1 IL10 MTOR VCAM1
20
Show member pathways
12.37 ICAM1 IFNG IL6 TNF
21
Show member pathways
12.37 CXCL8 IFNG IL6 TNF
22 12.34 HLA-G ICAM1 IFNG IL10
23
Show member pathways
12.31 CXCL8 IFNG IL6 TNF
24 12.28 IFNG IL10 IL6 TNF
25
Show member pathways
12.27 CXCL8 FAS IFNG IL6 TNF
26 12.23 CXCL8 IL10 IL6 TNF
27 12.21 CXCL8 HLA-G IL6 MTOR
28
Show member pathways
12.2 CXCL8 HLA-G IFNG IL10 IL6 TNF
29 12.17 HLA-G ICAM1 SELE VCAM1
30 12.17 ICAM1 IFNG SELE TNF VCAM1
31 12.16 HLA-G ICAM1 KIR3DL1 KLRB1 VCAM1
32 12.09 CXCL8 ICAM1 IFNG IL6 TNF
33 12.02 CXCL8 IFNG IL6 MTOR
34 12.02 IFNG IL10 IL2RA IL6 KLRB1 TNF
35
Show member pathways
12.01 IFNG IL10 IL6 TNF
36 11.99 CXCL8 ICAM1 IL10 IL6 TNF VCAM1
37 11.97 CXCL8 IFNG IL10 IL6 TNF
38
Show member pathways
11.96 IL6 MTOR TNF
39 11.96 CXCL8 ICAM1 TNF VCAM1
40 11.95 IFNG IL10 IL2RA IL6 MTOR
41 11.94 CXCL8 ICAM1 IFNG IL6 TNF
42 11.94 FAS ICAM1 IL6 SELE TNF VCAM1
43 11.92 IFNG IL6 MTOR
44 11.91 IL2RA IL6 TNF
45
Show member pathways
11.89 CXCL8 ICAM1 IL6
46 11.89 CXCL8 ICAM1 IFNG IL6 SELE
47 11.88 CXCL8 ICAM1 IL6 SELE TNF VCAM1
48 11.87 IFNG IL10 IL2RA KLRB1 TNF
49
Show member pathways
11.86 CXCL8 IFNG IL2RA TNF
50 11.86 CXCL8 IL10 IL6 TNF

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.65 FAS ICAM1 IL2RA TNF VCAM1
2 external side of plasma membrane GO:0009897 9.46 ICAM1 IL2RA TNF VCAM1
3 membrane raft GO:0045121 9.26 FAS ICAM1 SELE TNF
4 extracellular space GO:0005615 9.23 CXCL8 ICAM1 IFNG IL10 IL6 SELE

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA binding transcription factor activity GO:0051091 9.85 IL10 IL6 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.85 FAS IFNG MTOR TNF
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 ICAM1 IL6 MTOR
4 response to insulin GO:0032868 9.81 ICAM1 IL10 MTOR
5 B cell differentiation GO:0030183 9.8 IL10 RAG1 VCAM1
6 response to glucocorticoid GO:0051384 9.8 IL10 IL6 TNF
7 regulation of immune response GO:0050776 9.8 HLA-G ICAM1 KIR3DL1 KLRB1 VCAM1
8 positive regulation of T cell proliferation GO:0042102 9.79 IL2RA IL6 VCAM1
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 IL6 MTOR TNF
10 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
11 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.74 ICAM1 SELE VCAM1
12 extrinsic apoptotic signaling pathway GO:0097191 9.71 FAS IFNG TNF
13 negative regulation of T cell proliferation GO:0042130 9.7 HLA-G IL10 IL2RA
14 inflammatory response GO:0006954 9.7 CXCL8 FAS IL10 IL2RA IL6 SELE
15 regulation of osteoclast differentiation GO:0045670 9.68 MTOR TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
17 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
18 negative regulation of immune response GO:0050777 9.67 HLA-G IL2RA
19 interferon-gamma-mediated signaling pathway GO:0060333 9.67 HLA-G ICAM1 IFNG VCAM1
20 regulation of regulatory T cell differentiation GO:0045589 9.66 IFNG IL2RA
21 response to molecule of bacterial origin GO:0002237 9.66 CXCL8 IL10
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
23 cellular response to nutrient levels GO:0031669 9.65 ICAM1 MTOR
24 cellular response to lipopolysaccharide GO:0071222 9.65 CXCL8 ICAM1 IL10 IL6 TNF
25 negative regulation of lipid storage GO:0010888 9.64 IL6 TNF
26 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
27 leukocyte cell-cell adhesion GO:0007159 9.63 ICAM1 SELE VCAM1
28 positive regulation of nitric oxide biosynthetic process GO:0045429 9.62 ICAM1 IFNG MTOR TNF
29 leukocyte tethering or rolling GO:0050901 9.61 SELE TNF VCAM1
30 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.59 ICAM1 TNF
31 necroptotic signaling pathway GO:0097527 9.58 FAS TNF
32 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
33 membrane to membrane docking GO:0022614 9.56 ICAM1 VCAM1
34 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
37 response to lipopolysaccharide GO:0032496 9.43 FAS GJB2 ICAM1 IL10 SELE VCAM1
38 immune response GO:0006955 9.28 CXCL8 FAS IFNG IL10 IL2RA IL6
39 regulation of receptor activity GO:0010469 10.01 CXCL8 IFNG IL10 IL6 TNF

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 FAS GJB2 HLA-G MTOR RAG1 TNF
2 transmembrane signaling receptor activity GO:0004888 9.26 FAS ICAM1 KLRB1 SELE
3 cytokine activity GO:0005125 9.02 CXCL8 IFNG IL10 IL6 TNF

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....